

Index

Note: Page numbers of article titles are in **boldface** type.

A

- Aggresomes, in protein quality control, 1074
- Allogeneic cellular gene therapy, for hemoglobinopathies, **1145–1163**
- sickle cell anemia, 1155–1158
 - thalassemia, 1147–1155
- Alpha (α)-hemoglobin stabilizing protein gene, effect on clinical severity of HbE/ β -thalassemia, 1063
- Alpha (α)-thalassemia, inheritance of gene for, in patients with HbE/ β -thalassemia, 1061
- molecular basis of, competition for the upstream regulatory elements, 1045
 - deletions removing both of the duplicated structural genes, 1040–1042
 - deletions removing one of the duplicated structural genes, 1040
 - deletions removing the upstream regulatory elements of the α -globin gene cluster, 1044–1045
 - large deletions extending beyond the α -globin cluster with complex phenotypes (ATR-16 syndrome), 1045–1048
 - normal structure and regulation of human α -globin gene cluster, 1034–1035
 - normal variation within the human α -globin gene cluster, 1035–1037
 - rare mutation via an antisense RNA, 1042–1044
 - sequence variations in the structural genes, 1037
 - trans-acting mutations, 1048–1049
 - translocations and duplications of the α -globin cluster, 1037–1039
- Plasmodium falciparum* and, 1022–1024
- Antisense RNA, rare mutation causing α -thalassemia via, 1042–1044
- Ataxia telangiectasia, mouse models of, 1216–1217
- ATR-16 syndrome, causing α -thalassemia, 1045–1048
- Autophagy, in protein quality control, 1072
- in erythropoiesis, 1076

B

- Beta (β)-thalassemia, hemoglobin E (HbE) type, basis of marked clinical diversity, **1055–1070**
- adaptation to anemia as a modifying factor in, 1064–1065
 - clinical severity categories of, 1057–1060
 - environmental influences on phenotype of, 1065
 - epidemiology, 1055–1056
 - factors that influence the clinical severity of, 1060–1064
 - pathophysiology, 1056
 - recommendations for management of patients, 1065–1066
 - understanding the phenotypic heterogeneity of, 1056–1057
- hemoglobin gene therapy for, **1187–1201**
- globin gene therapy, 1188–1190

- Beta (β)-thalassemia (*continued*)
- mouse models, 1190
 - viruses as vectors, 1188–1190
 - human globin gene therapy, 1190–1197
 - current thalassemia clinical trial, 1192–1193
 - new homologous recombination approach to, 1196–1197
 - other approaches to, 1197
 - other lentiglobin trials, 1195–1196
 - results to date, 1194
 - safety issues, 1194–1195
 - unique human β -globin gene-containing vector, 1193
 - interacting factors leading to iron overload in, **1089–1107**
 - genetic causes, consequences, and pleiotropic effects, 1089–1091
 - ineffective erythropoiesis, 1092–1095
 - Epo/EpoR/Jak2/Stat5 pathway, 1092–1093
 - new studies on Jak2 and, 1093–1095
 - iron metabolism, 1095–1098
 - hepcidin and regulation of iron absorption, 1095–1097
 - role of hepcidin in, 1097–1098
 - mouse models of, 1091
 - questions and potential novel therapies, 1098–1101
 - hepcidin agonists or activators of hepcidin expression, 1099–1101
 - Jak2 inhibitors, 1098–1099
 - noninvasive prenatal diagnosis using fetal DNA in maternal plasma, **1179–1186**
 - Plasmodium falciparum* and, 1024
 - Bilirubin metabolism, effect on clinical severity of HbE/ β -thalassemia, 1063
 - Birt-Hogg-Dube disease, mouse models of, 1218
 - Bloom syndrome, mouse models of, 1217
 - Breast cancer, and Cowden disease, mouse models of, 1211–1213

C

- Cancer, mouse models of inherited syndromes, **1205–1228**
- breast cancer and Cowden disease, 1211–1213
 - familial endocrine and neural tumor syndromes, 1213–1216
 - Carney complex, 1216
 - multiple endocrine neoplasia type 1, 1215
 - neurofibromatosis (1 and 2), 1213–1214
 - paranglioma (succinate dehydrogenase), 1215
 - retinoblastoma, 1215
 - familial hematopoietic tumor syndromes, 1216–1217
 - ataxia telangiectasia, 1216–1217
 - Bloom syndrome, 1217
 - Fanconi anemia, 1217
 - Li-Fraumeni syndrome, 1216
 - familial kidney tumor syndromes, 1217–1218
 - Birt-Hogg-Dube disease, 1218
 - hereditary papillary renal cancer, 1218
 - von Hippel-Lindau disease, 1217–1218
 - familial skin cancer syndromes, 1218–1219
 - familial melanoma, 1219
 - nevroid basal cell carcinoma, 1219

Download English Version:

<https://daneshyari.com/en/article/3331800>

Download Persian Version:

<https://daneshyari.com/article/3331800>

[Daneshyari.com](https://daneshyari.com)